drugset / Trial / NCT02749019
Dual Integrin αvβ3 and GRPR Targeting PET Imaging in Breast Cancer Patients
Phase 1
Unknown
40 enrolled
Peking Union Medical College Hospital
National Institute for Biomedical Imaging and Bioengineering (NIBIB) · collab
NaSingle-groupOpen-labelDiagnostic
Summary
This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the diagnostic performance and evaluation efficacy of 68Ga-NOTA-BBN-RGD in breast cancer patients. A single dose of 111-148 Mega-Becquerel (MBq) 68Ga-NOTA-BBN-RGD will be injected intravenously. Visual and semiquantitative method will be used to assess the PET/CT images.
Timeline
- Start
- 2015-07
- Primary completion
- 2018-07
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 68Ga-NOTA-BBN-RGD | Peptide | 111 mbq | Intravenous |
| Subject | 68Ga-NOTA-BBN-RGD | Peptide | 148 mbq | Intravenous |